Stock Events

Stock Events

enGene Therapeutics 

$0.2200
15
+$0.00+0% Thursday 16:27

Statistics

Day High
0.22
Day Low
0.22
52W High
0.2398
52W Low
0.22
Volume
231
Avg. Volume
-
Mkt Cap
14.74M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

16SepExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
-0.73
-0.61
-0.49
-0.37
Expected EPS
-0.426644
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2023
2024
2025
0Revenue
-117.3MNet Income

Analyst Ratings

10.58Average Price Target
The highest estimate is 30.00.
From 9 ratings within the last 6 months. This is not an investment recommendation.
Buy
33%
Hold
56%
Sell
11%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ENGNW. It's not an investment recommendation.
NVIDIA
5
NVDA
Schwab US Dividend Equity
5
SCHD
JPMorgan Equity Premium Income
5
JEPI
Vanguard Morningstar Total Stock Market
5
VTI

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals focuses on developing treatments for cystic fibrosis and other diseases, overlapping with enGene's focus on gene therapy for gastrointestinal diseases.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is known for its work in CRISPR-Cas9 gene editing, a technology that can be applied similarly to enGene's gene delivery platforms.
Intellia Therapeutics
NTLA
Mkt Cap1.8B
Intellia Therapeutics is another key player in the CRISPR gene editing sector, directly competing with enGene's approach to gene therapy.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, similar to enGene's market.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, a field closely related to gene therapy, impacting similar therapeutic areas as enGene.
Ionis Pharmaceuticals
IONS
Mkt Cap10.15B
Ionis Pharmaceuticals focuses on RNA-targeted drug discovery and development, competing in the broader genetic medicine space with enGene.
uniQure N.V.
QURE
Mkt Cap3.38B
uniQure is involved in developing gene therapies for patients with severe genetic diseases, directly competing with enGene's therapeutic approaches.
Regenxbio
RGNX
Mkt Cap637.69M
REGENXBIO is a biotechnology company specializing in the development of gene therapy products, competing in the same innovative sector as enGene.

About

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
Show more...
CEO
Ronald H. W. Cooper
Employees
82
Country
Canada
ISIN
CA29286X1197

Listings

F
DE
S0N0.F
XNAS
US
ENGNW
XNAS
US
ENGN
BOATS
BOATS
ENGN.BOATS

0 Comments

Share your thoughts

FAQ

What is enGene Therapeutics stock price today?▼
The current price of ENGNW is $0.22 USD — it has increased by +0% in the past 24 hours. Watch enGene Therapeutics stock price performance more closely on the chart.
What is enGene Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange enGene Therapeutics stocks are traded under the ticker ENGNW.
What is enGene Therapeutics market cap?▼
Today enGene Therapeutics has the market capitalization of 14.74M
When is the next enGene Therapeutics earnings date?▼
enGene Therapeutics is going to release the next earnings report on September 16, 2026.
What were enGene Therapeutics earnings last quarter?▼
ENGNW earnings for the last quarter are -0.43 USD per share, whereas the estimation was -0.47 USD resulting in a +7.76% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is enGene Therapeutics revenue for the last year?▼
enGene Therapeutics revenue for the last year amounts to 0 USD.
What is enGene Therapeutics net income for the last year?▼
ENGNW net income for the last year is -117.3M USD.
How many employees does enGene Therapeutics have?▼
As of September 04, 2026, the company has 82 employees.
In which sector is enGene Therapeutics located?▼
enGene Therapeutics operates in the Health & Wellness sector.
When did enGene Therapeutics complete a stock split?▼
enGene Therapeutics has not had any recent stock splits.
Where is enGene Therapeutics headquartered?▼
enGene Therapeutics is headquartered in SAINT-LAURENT, Canada.